Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients.
de Vries S, Schaapveld M, Janus CPM, Daniëls LA, Petersen EJ, van der Maazen RWM, Zijlstra JM, Beijert M, Nijziel MR, Verschueren KMS, Kremer LCM, van Eggermond AM, Lugtenburg PJ, Krol ADG, Roesink JM, Plattel WJ, van Spronsen DJ, van Imhoff GW, de Boer JP, Aleman BMP, van Leeuwen FE. de Vries S, et al. Among authors: van imhoff gw. J Natl Cancer Inst. 2021 Jun 1;113(6):760-769. doi: 10.1093/jnci/djaa194. J Natl Cancer Inst. 2021. PMID: 33351090 Free PMC article.
Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.
Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, Roesink J, Raemaekers JM, de Boer JP, Zijlstra JM, van Imhoff GW, Petersen EJ, Poortmans PM, Beijert M, Lybeert ML, Mulder I, Visser O, Louwman MW, Krul IM, Lugtenburg PJ, van Leeuwen FE. Schaapveld M, et al. Among authors: van eggermond am, van der maazen rw, van leeuwen fe, van imhoff gw. N Engl J Med. 2015 Dec 24;373(26):2499-511. doi: 10.1056/NEJMoa1505949. N Engl J Med. 2015. PMID: 26699166 Free article.
Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer.
Rigter LS, Schaapveld M, Janus CPM, Krol ADG, van der Maazen RWM, Roesink J, Zijlstra JM, van Imhoff GW, Poortmans PMP, Beijert M, Lugtenburg PJ, Visser O, Snaebjornsson P, van Eggermond AM, Aleman BMP, van Leeuwen FE, van Leerdam ME. Rigter LS, et al. Among authors: van imhoff gw. Cancer Med. 2019 Jan;8(1):190-199. doi: 10.1002/cam4.1922. Epub 2018 Dec 27. Cancer Med. 2019. PMID: 30592184 Free PMC article.
Interim thymus and activation regulated chemokine versus interim 18 F-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation.
Plattel WJ, Visser L, Diepstra A, Glaudemans AWJM, Nijland M, van Meerten T, Kluin-Nelemans HC, van Imhoff GW, van den Berg A. Plattel WJ, et al. Among authors: van imhoff gw. Br J Haematol. 2020 Jul;190(1):40-44. doi: 10.1111/bjh.16514. Epub 2020 Feb 27. Br J Haematol. 2020. PMID: 32106342 Free PMC article.
Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study.
Hagenbeek A, Mooij H, Zijlstra J, Lugtenburg P, van Imhoff G, Nijland M, Tonino S, Hutchings M, Spiering M, Liu R, van Tinteren H, Kersten MJ. Hagenbeek A, et al. Haematologica. 2019 Apr;104(4):e151-e153. doi: 10.3324/haematol.2018.196899. Epub 2018 Oct 31. Haematologica. 2019. PMID: 30381303 Free PMC article. Clinical Trial. No abstract available.
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial.
Vellenga E, van Putten WL, van 't Veer MB, Zijlstra JM, Fibbe WE, van Oers MH, Verdonck LF, Wijermans PW, van Imhoff GW, Lugtenburg PJ, Huijgens PC. Vellenga E, et al. Among authors: van putten wl, van oers mh, van t veer mb, van imhoff gw. Blood. 2008 Jan 15;111(2):537-43. doi: 10.1182/blood-2007-08-108415. Epub 2007 Oct 30. Blood. 2008. PMID: 17971487 Free article. Clinical Trial.
128 results